Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is radical radiotherapy effective in patients with pT1G3 NXM0 bladder cancer?

Nature Clinical Practice Urology volume 5, pages 22–23 (2008)Cite this article

boxed-textHarland SJ et al. (2007) A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol 178: 807–813

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Herr HW (2005) Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette–Guerin therapy. J Urol 174: 2134–2137

    Article  Google Scholar 

  2. Cookson MS et al. (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158: 62–67

    Article  CAS  Google Scholar 

  3. Herr HW et al. (2007) Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy. J Urol 177: 75–79

    Article  Google Scholar 

  4. Raj GV et al. (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177: 1283–1286

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Murphy, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Urology, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA herrh@mskcc.org

Authors and Affiliations

  1. HW Herr is Director of Bladder Cancer Research, and a Urologic Surgeon at Memorial Sloan–Kettering Cancer Center, and Professor of Urology at Cornell University Medical College, New York, NY, USA.,

    Harry W Herr

Authors
  1. Harry W Herr
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herr, H. Is radical radiotherapy effective in patients with pT1G3 NXM0 bladder cancer?. Nat Rev Urol 5, 22–23 (2008). https://doi.org/10.1038/ncpuro0976

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0976

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing